<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357237</url>
  </required_header>
  <id_info>
    <org_study_id>PEDXIL 01</org_study_id>
    <nct_id>NCT03357237</nct_id>
  </id_info>
  <brief_title>EFFICACY AND SAFETY OF XILOGLUCAN IN ACUTE GASTROENTERITIS IN CHILDREN</brief_title>
  <acronym>PEDXIL01</acronym>
  <official_title>RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE EFFICACY AND SAFETY OF XILOGLUCAN IN ACUTE GASTROENTERITIS IN CHILDREN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enriqueta Roamn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute gastroenteritis (GEA) is an inflammation of the intestinal mucosa that clinically&#xD;
      translates into an acute episode of diarrhea and vomiting and is generally associated with an&#xD;
      intestinal infectious disease. It is one of the most common diseases in children and an&#xD;
      important cause of morbidity and mortality worldwide. The important loss of liquids can lead&#xD;
      to dehydration, acidosis and hydroelectrolitic alteration. Infants are more vulnerable to&#xD;
      gastrointestinal infection and its consequences, dehydration and malnutrition.&#xD;
&#xD;
      There is no specific treatment, so it is exclusively symptomatic&#xD;
&#xD;
      A new type of products considered as mucoprotectors has been developed, such as gelatin&#xD;
      tannate or xyloglucan, still with little data to establish recommendations on its use in the&#xD;
      GEA. They would be able to reproduce in the intestine a muco-adhesive film or sheet&#xD;
      protective It must be considered in this sense that mucus is the first barrier that protects&#xD;
      the gastrointestinal tract against microorganisms or antigens and that bacterial invasion is&#xD;
      related to the opening of narrow junctions.&#xD;
&#xD;
      Xyloglucan was approved in Europe as a medical device IIa to restore the physiological&#xD;
      functions of the intestinal wall in the form of capsules for adults and envelopes for&#xD;
      children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, blinded study with a control group is proposed in this project to establish&#xD;
      solidly the efficacy of xyloglucan in the treatment of acute gastroenteritis in children.&#xD;
&#xD;
      The main variable of evaluation will be the duration of diarrhea, defined as the time it&#xD;
      takes to normalize the consistency of stools (according to the Bristol or Amsterdam scale) or&#xD;
      their number.&#xD;
&#xD;
      Clinical trial in phase IV with medical product type IIa and CE marking, used in the same&#xD;
      conditions in which it is marketed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">July 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan&#xD;
Control or reference group: treatment regimen with oral rehydration solution and placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time of resolution of diarrhea</measure>
    <time_frame>14 days</time_frame>
    <description>Number of days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>XYLOGLUCAN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment regimen with oral rehydration solution and xyloglucan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>rehydration solution and placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical device</intervention_name>
    <description>patients will be assigned, following an external randomization, to two groups:&#xD;
Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan&#xD;
Control or reference group: treatment regimen with oral rehydration solution and placebo</description>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_label>XYLOGLUCAN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical of acute gastroenteritis: change in the consistency of stools to &quot;loose&quot; or&#xD;
             liquid according to Bristol scale (6 or 7) or Amsterdam (infants) (A) and / or&#xD;
             increase in the number of stools (greater or equal to 3 / day) with a duration of less&#xD;
             than 72 h&#xD;
&#xD;
          -  Age over 3 months and under 5 years&#xD;
&#xD;
          -  Written informed consent according to ICH / GCP and local legislation, obtained before&#xD;
             any study procedure of parents or guardians&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with antibiotics, xyloglucan, gelatin tannate, racecadotril, smectite,&#xD;
             probiotics or zinc (including oral rehydration solution containing zinc and / or&#xD;
             probiotics) in the previous week&#xD;
&#xD;
          -  Exclusive breastfeeding&#xD;
&#xD;
          -  Chronic gastrointestinal disease (celiac disease, cystic fibrosis, inflammatory bowel&#xD;
             disease, food allergy)&#xD;
&#xD;
          -  Immunodeficiencies&#xD;
&#xD;
          -  Malnutrition (weight / height / length less than P3 according to WHO standards)&#xD;
&#xD;
          -  Severe dehydration&#xD;
&#xD;
          -  Impossibility of follow-up&#xD;
&#xD;
          -  Known hypersensitivity to gelatin or xyloglucan&#xD;
&#xD;
          -  Absence of informed consent&#xD;
&#xD;
          -  Caregivers / parents who can not understand or comply with all the instructions and&#xD;
             requirements of the study.&#xD;
&#xD;
          -  If in the opinion of the researcher there are findings in the physical examination,&#xD;
             abnormalities in the results of the clinical analyzes or other medical, social or&#xD;
             psychosocial factors that could negatively influence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enriqueta Roman, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Puerta de Hierro Majadahonda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Jose Garcia, MD</last_name>
    <phone>34911 91 60 00</phone>
    <email>mariajo_p_G@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>November 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>Enriqueta Roamn</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

